Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15005MR)

This product GTTS-WQ15005MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15005MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8808MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ4273MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ4208MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ951MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ12652MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ3638MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ9390MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ1182MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW